SinoMab BioScience Ltd

HKSE:03681 (Hong Kong)  
HK$ 1.79 (-1.65%) May 16
At Loss
P/B:
5.77
Market Cap:
HK$ 1.95B ($ 250.40M)
Enterprise V:
HK$ 2.22B ($ 284.55M)
Volume:
108.90K
Avg Vol (2M):
244.87K
Volume:
108.90K
At Loss
Avg Vol (2M):
244.87K

Business Description

Description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Name Current Vs Industry Vs History
Cash-To-Debt 0.52
Equity-to-Asset 0.35
Debt-to-Equity 1.53
Debt-to-EBITDA -1.91
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.19
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 42.25
9-Day RSI 47.19
14-Day RSI 53.63
6-1 Month Momentum % 66.06

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.56
Quick Ratio 1.56
Cash Ratio 1.36

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.9
Shareholder Yield % -4.64

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 30.94
Operating Margin % -16818.75
Net Margin % -17810.45
FCF Margin % -17416.88
ROE % -59.68
ROA % -26.19
ROIC % -36.11
ROC (Joel Greenblatt) % -42.66
ROCE % -31.6

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1790
PB Ratio 5.77
Price-to-Tangible-Book 5.77
EV-to-EBIT -8.58
EV-to-EBITDA -8.58
EV-to-Revenue 1487.41
EV-to-FCF -8.54
Earnings Yield (Greenblatt) % -11.66
FCF Yield % -13.31

Financials

HKSE:03681's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

SinoMab BioScience Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil HK$) 1.493
EPS (TTM) (HK$) -0.262
Beta 0.25
Volatility % 55.91
14-Day RSI 53.63
14-Day ATR (HK$) 0.069341
20-Day SMA (HK$) 1.872
12-1 Month Momentum % 0
52-Week Range (HK$) 1.03 - 1.95
Shares Outstanding (Mil) 1,091.76

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

SinoMab BioScience Ltd Filings

Filing Date Document Date Form
No Filing Data

SinoMab BioScience Ltd Stock Events

Financials Calendars
Event Date Price(HK$)
No Event Data

SinoMab BioScience Ltd Frequently Asked Questions

What is SinoMab BioScience Ltd(HKSE:03681)'s stock price today?
The current price of HKSE:03681 is HK$1.79. The 52 week high of HKSE:03681 is HK$1.95 and 52 week low is HK$1.03.
When is next earnings date of SinoMab BioScience Ltd(HKSE:03681)?
The next earnings date of SinoMab BioScience Ltd(HKSE:03681) is .
Does SinoMab BioScience Ltd(HKSE:03681) pay dividends? If so, how much?
SinoMab BioScience Ltd(HKSE:03681) does not pay dividend.

Press Release

Subject Date
No Press Release